Pharmaceutical

EC grants approval to Merck’s Keytruda for gastric cancer

The EC has granted approval for Merck’s Keytruda regimen for gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Aug 30, 2023 - 20:00
EC grants approval to Merck’s Keytruda for gastric cancer
The EC has granted approval for Merck’s Keytruda regimen for gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Read the original article

Tags:

Previous Article

Biostax and Immgenuity to expedite HIV immunotherapies development

Next Article

Alvotech and Bioventure gain approval for Humira biosimilar in Egypt

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We’re reading about worries over a Novo deal, a PBM bill, and more

STAT+: Pharmalittle: We’re reading about worries over a...

Feb 7, 2024

Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases

Sandoz’s Afqlir gains EC marketing authorisation for re...

Nov 19, 2024

Studies show top surgery is safe for fat patients, but some surgeons still mandate weight loss

Studies show top surgery is safe for fat patients, but ...

Jun 2, 2023